Continuing Education Activity

Disulfiram is a Food and Drug Administration-approved medication for alcohol dependence. This activity discusses disulfiram's use as an intervention for both short and long-term management of alcohol dependency in motivated individuals. Participants will explore its mechanism of action, adverse event profile, contraindications, pharmacology, monitoring protocols, and pertinent drug interactions, facilitating a comprehensive understanding among healthcare team members. This knowledge equips professionals to tailor treatment strategies to individual patient needs, fostering informed decision-making while mitigating potential adverse effects. By focusing on the pharmacological intricacies of disulfiram, healthcare providers gain the knowledge to administer personalized care, thereby aiding patients on their journey to sobriety.

Objectives:

• Identify the Food and Drug Administration-approved indications for disulfiram therapy.
• Identify the mechanism of action of disulfiram corresponding to its indicated use.
• Evaluate the adverse drug reactions of disulfiram.
• Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from disulfiram therapy.

Indications

Disulfiram is 1 of 3 drugs approved by the Food and Drug Administration for the treatment of alcohol dependence.

Food and Drug Administration-Approved Indication

It is a second-line option (acamprosate and naltrexone are first-line treatments) in patients with sufficient physician supervision. Disulfiram is safe and efficient in supervised short-term and long-term treatment of individuals dependent on alcohol but who are motivated to discontinue alcohol use.[1] The American Psychiatric Association (APA) 2018 guidelines endorse the use of disulfiram for alcohol use disorder. According to APA recommendations, disulfiram should be considered for patients exhibiting moderate to severe alcohol use disorder under specific conditions. This includes individuals with a primary goal of achieving abstinence and those who express a preference for disulfiram or demonstrate intolerance or lack of response to naltrexone and acamprosate. Furthermore, candidates for disulfiram treatment should possess the capability to comprehend the risks associated with alcohol consumption while taking the medication, and they should have no contraindications to its use.[2]

Off-Label Uses

Current studies for treating patients with comorbid alcohol dependence with post-traumatic stress disorder, alcohol and cocaine dependence, and cocaine dependence alone are underway.[3][4][5] A systematic review presents promising evidence regarding the efficacy of disulfiram as a potential intervention for cocaine dependence. The synthesis of data from 13 studies, encompassing 1191 individuals with cocaine addiction, indicates a potential increase in abstinence rates at the end of treatment when comparing disulfiram to a placebo. However, uncertainties persist concerning its impact on both the frequency and quantity of cocaine use. Disulfiram appears to demonstrate a potential advantage in reducing the frequency of cocaine use when contrasted with naltrexone, although its effect on the quantity of cocaine use remains uncertain.[6] Recent studies of disulfiram as a proteasome inhibitor and deoxyribonucleic acid (DNA) demethylating agent show promise for new potential therapeutic uses for malignancy and fungal infections. Disulfiram may have a primary or adjuvant role in treating drug-resistant fungal infections (particularly Candida) and malignancy by inhibiting the ABC drug transport protein responsible for resistance. In addition, evidence shows that metabolites of disulfiram induce p53, mediating apoptosis and cell death. Investigations of the role of disulfiram as an anti-cancer and antimicrobial agent are ongoing.[7][8][9]

Mechanism of Action

Disulfiram converts to an active metabolite, diethyldithiocarbamate, in the stomach. In the blood, it changes to diethyldithiocarbamic acid (DDC), which is degraded to form diethylamine and carbon disulfide. DDC undergoes phase II metabolism, forming sulfoxide and sulfone metabolites. These S-oxidized compounds are potent active metabolites producing the effects of disulfiram.[10][11][12]

Alcohol Dependence

Disulfiram irreversibly inhibits aldehyde dehydrogenase (ALDH1A1) by competing with nicotinamide adenine dinucleotide (NAD) at the cysteine residue in the enzyme's active site. Aldehyde dehydrogenase is a hepatic enzyme of the major oxidative pathway of alcohol metabolism, converting acetaldehyde to acetate. At therapeutic doses of disulfiram, alcohol consumption results in increased serum acetaldehyde, causing diaphoresis, palpitations, facial flushing, nausea, vertigo, hypotension, and tachycardia. This aggregation of symptoms is known as the disulfiram-alcohol reaction and discourages alcohol intake. The reaction is proportional to both the dose of disulfiram and alcohol. Thus, disulfiram is not an anti-craving drug and does not modulate the neurobiological mechanism of addiction.

Cocaine Dependence

Disulfiram also inhibits dopamine beta-hydroxylase (DBH), an enzyme that converts dopamine to noradrenaline, causing an accumulation of dopamine. Increased dopamine corrects the underlying deficit in patients addicted to cocaine. Recent studies have shown reduced frequency and amount of cocaine use in patients treated with disulfiram.

Pharmacokinetics

Absorption: Disulfiram is readily absorbed by the gastrointestinal tract, with an 80% to 90% absorption following oral administration.

Distribution: Disulfiram's high lipid solubility facilitates its widespread distribution into fatty tissue throughout the body, and its ability to cross the blood-brain barrier increases its distribution into the central nervous system.

Metabolism: Disulfiram undergoes extensive metabolism in vivo, primarily through reduction, leading to diethyldithiocarbamate (DDTC) formation. DDTC's metabolic fate includes spontaneous degradation in acidic environments like the stomach, yielding diethylamine and carbon disulfide. Another pathway involves the formation of a glucuronide of DDTC through the action of the enzyme glucuronosyltransferase in the liver, contributing to a fraction of the drug excreted in urine. Additionally, thiol methyltransferase enzymes catalyze the methylation of DDTC, resulting in the formation of the lipophilic metabolite DDTC-Me, which plays a role in the irreversible inhibition of the aldehyde dehydrogenase enzyme.[7]

Elimination: Human studies suggest half-lives of 7 hours for disulfiram and 15 hours for DDTC, indicating significant inter-subject variability in the levels of disulfiram and its metabolites following oral administration.

Administration

Available Dosage Forms and Strengths

Disulfiram is available only via oral administration. Tablets are available in 250 mg to 500 mg forms.

Adult Dosage

Disulfiram tablets may be crushed and mixed with liquids (water, coffee, milk, fruit juice) and should be taken once per day. Disulfiram administration should never take place until the patient has abstained from alcohol for at least 12 hours. Patients should avoid alcohol and alcohol-containing products for at least 14 days after discontinuing disulfiram, as there are reports of disulfiram-alcohol reactions within 2 weeks of discontinuation. There is no benefit to increasing the dose of disulfiram to greater than 500 mg/d. A trial of disulfiram and alcohol to produce a disulfiram-alcohol reaction is no longer a recommendation. However, the patient should receive extensive education on symptoms of disulfiram-alcohol reaction before administration.

Specific Patient Populations

Hepatic impairment: According to recent guidelines from the American College of Gastroenterology (ACG), disulfiram should not be used in individuals with liver disease of any spectrum. This is because disulfiram is completely metabolized by the liver and is associated with hepatotoxicity. The use of disulfiram has been linked to idiosyncratic liver injury characterized by an immunoallergenic mechanism. While this adverse reaction is rare, it appears to be more common in individuals with pre-existing liver disease. Additionally, disulfiram does not demonstrate efficacy in preventing the development or progression of liver disease in individuals with Alcohol Use Disorder (AUD).[13]

Renal impairment: There are no dosage adjustments for disulfiram provided in the product labeling; use with caution.

Pregnancy considerations: The utilization of disulfiram during pregnancy lacks established safety. Therefore, the administration of disulfiram in pregnant individuals should be considered only if, according to the physician's assessment, the anticipated benefits outweigh the potential risks.

Breastfeeding considerations: There is a lack of clinical data regarding the administration of disulfiram during breastfeeding. Alternative medications can be considered, particularly when nursing a preterm infant. The drug's labeling advises against the use of disulfiram in nursing mothers.[14]

Pediatric patients: The safety and effectiveness of disulfiram in pediatric patients have not been established.

Older patients: Careful dosage selection of disulfiram is essential for older patients, typically initiating at the lower dosing range. This approach considers the higher occurrence of reduced hepatic, cardiac, or renal function and the presence of concurrent diseases or simultaneous drug treatments.

Adverse Effects

Disulfiram has an acceptable risk profile. However, it is associated with many adverse events and drug-drug interactions, including death. The most common and less serious adverse effects include headache, sleepiness, tiredness, and halitosis (or metallic taste).[11][15][16][17] Dermatological, neurological, psychiatric, and cardiac events have been reported. Serious adverse effects include hepatitis, hepatotoxicity, psychosis, seizures, peripheral neuropathy, and optic neuritis. Dermatological adverse effects are rare and include exfoliative dermatitis, rash, and pruritis. Hepatic failure may develop after many months of therapy. There have been cases of fatal fulminant hepatic failure that have been reported despite discontinuation of medication (1 in 30,000 patients treated per year).

Psychiatric adverse effects are rare. Psychosis, confusional states, mutism, headbanging, memory impairment, and rarely stupor have been reported, and effects are dose-dependent. Symptoms usually resolve after discontinuation of disulfiram and a short course of antipsychotic medication. Psychosis may occur as a result of an interaction between disulfiram and cannabis. Neurological adverse effects may occur as early as 10 days after initiation. Axonal polyneuropathy is a rare adverse effect. Some cases of severe sensory-motor polyneuropathy with the involvement of cranial nerves have been reported within weeks of initiation of disulfiram 500 mg. Neuropathy occurs in 1 per 1000 patients treated with disulfiram per year.

Drug-Drug Interactions

Drug interactions occur with compounds utilizing the cytochrome P450 enzyme system for oxidative metabolism.[7] This interaction can occur with the following medications: amitriptyline, imipramine, phenytoin, chlordiazepoxide, diazepam, omeprazole, and acetaminophen. Drug-drug interactions may occur with other medications not listed. Slow elimination of disulfiram may give rise to the disulfiram-alcohol reaction up to 14 days after the discontinuation. Disulfiram-alcohol reactions have been reported in patients exposed to environmental chemical compounds containing alcohol. Prolonged administration of disulfiram has demonstrated the inhibition of the metabolism of theophylline, phenytoin, and warfarin.[18]

Contraindications

Disulfiram is not a safe option for everyone. Disulfiram is contraindicated absolutely in patients with significant coronary artery disease or heart failure. Cases of heart failure and death have occurred in patients with severe myocardial disease shortly after the initiation of disulfiram. Disulfiram is contraindicated with psychosis as it may worsen the patient's psychosis. Caution is necessary for patients with a history of liver disease, and the physician must weigh the risks versus benefits. Patients receiving metronidazole, paraldehyde, alcohol, or alcohol-containing preparations (sauces, cough mixtures, vinegar) should not receive disulfiram and should be educated in advance to avoid a disulfiram-alcohol reaction. Disulfiram should never be administered to a patient if alcohol use is suspected or without the patient's consent and understanding of the disulfiram-alcohol reaction. Disulfiram may be a therapeutic option with caution in patients with seizures, diabetes, thyroid disorders, traumatic brain injury, and renal disease due to the possibility of an accidental disulfiram-alcohol reaction.

Box Warning

Disulfiram should never be administered when patients are in a state of alcohol intoxication or without their full knowledge. The clinician should instruct relatives accordingly.

Precautions

In a cross-sectional survey of disulfiram-treated patients, adverse reactions were observed when using alcohol-based hand rubs, common products during the COVID-19 pandemic. This emphasizes the importance of caution and considering alternative hand hygiene methods for individuals on disulfiram.[19]

Monitoring

Close monitoring of adverse events is necessary, particularly in patients with polysubstance abuse. Patients taking disulfiram require monitoring for signs and symptoms of hepatitis, including fatigue, weakness, anorexia, nausea, vomiting, jaundice, malaise, and dark urine.[20] Baseline and follow-up liver function tests should be monitored 10 days to 1 month following initiation of disulfiram. Complete blood count and serum chemistries should also require routine monitoring.

Toxicity

Signs and Symptoms of Overdose

One case report features a 4-year-old girl who accidentally ingested 4–5 tablets of disulfiram, resulting in hypoglycemia and encephalopathy. After management in the intensive care unit, the child exhibited normalization of blood sugars after 8 hours and displayed characteristic MRI brain findings, including bilateral globus pallidus hyperintensity in T2-weighted and diffusion-weighted images. The conclusion underscores the potential severity of acute disulfiram poisoning in children and emphasizes the importance of considering it in the diagnosis of idiopathic encephalopathy with extrapyramidal symptoms.[21]

Management of Overdose

Contact the local poison control center in case of an overdose. No information is available on the treatment of disulfiram overdose, and there is no antidote available. Supportive care via supplemental oxygen, cardiac monitoring, and intravenous fluids may be necessary. Consult a physician if symptoms are severe. Cases of ingestion of 5 g or greater resulted in parkinsonism, choreoathetosis, and thalamic syndrome. Doses should not exceed 500 mg/d for treatment of alcohol dependence, and doses for malignancy remain as yet undetermined.

Enhancing Healthcare Team Outcomes

Disulfiram may be prescribed by the primary care provider, psychiatrist, nurse practitioner, or physician assistant. However, all healthcare workers, including the nursing staff and pharmacist, must be familiar with its adverse effect profile. The agent is not well tolerated, and when consumed with alcohol, it can produce severe adverse effects that can even lead to a heart attack. Today, this drug is not used to treat alcoholism because it is not deemed to be safe.[22] When using disulfiram requires an interprofessional team approach. Prescribing was covered in the previous paragraph, and the pharmacist should have input regarding dosing and drug-drug interactions by performing complete medication reconciliation and reporting any concerns to the prescribing clinician. Nurses should monitor for treatment effectiveness and adverse reactions to disulfiram and alert the team should any significant adverse event occur. An interprofessional team approach and open communication among healthcare professionals, including nurses, specialists, and pharmacists, can optimize patient outcomes related to disulfiram therapy.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Stokłosa I, Więckiewicz G, Stokłosa M, Piegza M, Pudlo R, Gorczyca P. Medications for the Treatment of Alcohol Dependence-Current State of Knowledge and Future Perspectives from a Public Health Perspective. Int J Environ Res Public Health. 2023 Jan 19;20(3) [PMC free article: PMC9915396] [PubMed: 36767234]

2.

Reus VI, Fochtmann LJ, Bukstein O, Eyler AE, Hilty DM, Horvitz-Lennon M, Mahoney J, Pasic J, Weaver M, Wills CD, McIntyre J, Kidd J, Yager J, Hong SH. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. Am J Psychiatry. 2018 Jan 01;175(1):86-90. [PubMed: 29301420]

3.

Butler K, Le Foll B. Impact of Substance Use Disorder Pharmacotherapy on Executive Function: A Narrative Review. Front Psychiatry. 2019;10:98. [PMC free article: PMC6405638] [PubMed: 30881320]

4.

Williams JB. Use of Disulfiram for Treatment of Alcohol Addiction in Patients With Psychotic Illness. Am J Psychiatry. 2019 Jan 01;176(1):80-81. [PubMed: 30848944]

5.

Warren D. Prescription Drug and Alcohol Use Disorders: Alcohol Use Disorder. FP Essent. 2019 Mar;478:30-42. [PubMed: 30844223]

6.

Traccis F, Minozzi S, Trogu E, Vacca R, Vecchi S, Pani PP, Agabio R. Disulfiram for the treatment of cocaine dependence. Cochrane Database Syst Rev. 2024 Jan 05;1(1):CD007024. [PMC free article: PMC10767770] [PubMed: 38180268]

7.

Lanz J, Biniaz-Harris N, Kuvaldina M, Jain S, Lewis K, Fallon BA. Disulfiram: Mechanisms, Applications, and Challenges. Antibiotics (Basel). 2023 Mar 06;12(3) [PMC free article: PMC10044060] [PubMed: 36978391]

8.

Lajarin-Reinares M, Pena-Rodríguez E, Cañellas-Santos M, Rosell-Vives E, Cortés P, Casas ML, Calvo MÀ, Fernandez-Campos F. Repurposing Disulfiram as an Antimicrobial Agent in Topical Infections. Antibiotics (Basel). 2022 Dec 04;11(12) [PMC free article: PMC9774419] [PubMed: 36551409]

9.

Karsa M, Xiao L, Ronca E, Bongers A, Spurling D, Karsa A, Cantilena S, Mariana A, Failes TW, Arndt GM, Cheung LC, Kotecha RS, Sutton R, Lock RB, Williams O, de Boer J, Haber M, Norris MD, Henderson MJ, Somers K. FDA-approved disulfiram as a novel treatment for aggressive leukemia. J Mol Med (Berl). 2024 Apr;102(4):507-519. [PMC free article: PMC10963497] [PubMed: 38349407]

10.

Budworth L, Prestwich A, Lawton R, Kotzé A, Kellar I. Preoperative Interventions for Alcohol and Other Recreational Substance Use: A Systematic Review and Meta-Analysis. Front Psychol. 2019;10:34. [PMC free article: PMC6369879] [PubMed: 30778307]

11.

Williams EC, Matson TE, Harris AHS. Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions. Addict Sci Clin Pract. 2019 Feb 12;14(1):6. [PMC free article: PMC6371480] [PubMed: 30744686]

12.

Heldal AT, Skurtveit S, Lobmaier PPK, Vederhus JK, Bramness JG. [Use of drugs for alcohol use disorder in Norway 2004–16]. Tidsskr Nor Laegeforen. 2018 Nov 13;138(18) [PubMed: 30421743]

13.

Jophlin LL, Singal AK, Bataller R, Wong RJ, Sauer BG, Terrault NA, Shah VH. ACG Clinical Guideline: Alcohol-Associated Liver Disease. Am J Gastroenterol. 2024 Jan 01;119(1):30-54. [PMC free article: PMC11040545] [PubMed: 38174913]

14.

Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Sep 19, 2022. Disulfiram. [PubMed: 36153943]

15.

Kranzler HR, Soyka M. Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review. JAMA. 2018 Aug 28;320(8):815-824. [PMC free article: PMC7391072] [PubMed: 30167705]

16.

Blanco-Gandía MC, Rodríguez-Arias M. Pharmacological treatments for opiate and alcohol addiction: A historical perspective of the last 50 years. Eur J Pharmacol. 2018 Oct 05;836:89-101. [PubMed: 30096298]

17.

Guerzoni S, Pellesi L, Pini LA, Caputo F. Drug-drug interactions in the treatment for alcohol use disorders: A comprehensive review. Pharmacol Res. 2018 Jul;133:65-76. [PubMed: 29719204]

18.

Frye RF, Branch RA. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects. Br J Clin Pharmacol. 2002 Feb;53(2):155-62. [PMC free article: PMC1874301] [PubMed: 11851639]

19.

Ghosh A, Mahintamani T, Balhara YPS, Roub FE, Basu D, Bn S, Mattoo SK, Mishra E, Sharma B. Disulfiram Ethanol Reaction with Alcohol-Based Hand Sanitizer: An Exploratory Study. Alcohol Alcohol. 2021 Jan 04;56(1):42-46. [PMC free article: PMC7665335] [PubMed: 33150930]

20.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Sep 7, 2021. Disulfiram. [PMC free article: PMC547852] [PubMed: 31643433]

21.

Bhalla K, Mittal K, Gupta A, Nehra D. Acute Disulfiram Poisoning in a Child: A Case Report and Review of Literature. Indian J Crit Care Med. 2020 Mar;24(3):203-205. [PMC free article: PMC7225768] [PubMed: 32435101]

22.

Antonelli M, Ferrulli A, Sestito L, Vassallo GA, Tarli C, Mosoni C, Rando MM, Mirijello A, Gasbarrini A, Addolorato G. Alcohol addiction - the safety of available approved treatment options. Expert Opin Drug Saf. 2018 Feb;17(2):169-177. [PubMed: 29120249]

Disclosure: Maranda Stokes declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.

Disclosure: Sara Abdijadid declares no relevant financial relationships with ineligible companies.